Several companies declared their quarterly financial results before the market opened, while many companies are scheduled to report their earnings after the closing bell today. Some notable earners are discussed here.
Sony Corp. (NYSE: SNE), which designs, develops, manufactures, and sells electronic equipments, instruments and devices, reported its fiscal 2011 second quarter earnings early today. Its net loss attributable to stockholders that exclude net income attributable to non-controlling interests was 27 billion yen or $350 million, or $0.35 per share, compared to net income of 31.1 billion yen in the same quarter of the previous fiscal year. Analysts estimated a net profit of $0.31 per share for the company. The company's sales were 1,575.0 billion yen or $20,454 million, a decrease of 9.1 percent compared to the same quarter of the previous fiscal year primarily due to unfavorable foreign exchange rates and a decrease in sales in the CPS segment, which was mainly affected by a decrease in sales of LCD televisions. During the quarter, operating loss of 1.6 billion yen or $21 million was recorded, compared to operating income of 68.7 billion yen in the same quarter of the previous fiscal year.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), a leading pharmaceutical company, announced its FY 2011 Q3 earnings early today. During the quarter, the company reported non-GAAP net income and non-GAAP EPS of $1,111 million and $1.25, compared to $1,182 million and $1.30, respectively, in the third quarter of 2010, and $984 million and $1.10, respectively, in the second quarter of 2011. Quarterly GAAP net income was $916 million, compared to $1,050 million in the third quarter of 2010 and $576 million in the second quarter of 2011; GAAP EPS totaled $1.03, compared to $1.15 in the third quarter of 2010 and $0.64 in the second quarter of 2011. Analysts had estimated a net profit of $1.23 per share for the company. The company recorded net sales of $4.34 billion, compared to $4.25 billion in the third quarter of 2010, an increase of 2 percent and $4.21 billion in the second quarter of 2011, an increase of 3 percent. Sales in North America in the third quarter were $2,183 million, representing 50 percent of total sales, a decrease of 20 percent. Generic and other sales in the US were $845 million in the quarter, down 48 percent. Sales in Europe in the third quarter of 2011 were $1,344 million, up 34 percent, accounting for 31 percent of total sales.
Becton, Dickinson and Co. (NYSE: BDX), a leading medical technology company, announced its FY 2011 Q4 financial results today. It recorded 24 percent decline in its Q4 earnings to $300 million, or $1.36 a share, down from $396.7 million, or $1.68 a share, a year earlier. The latest period included a per-share loss from discontinued operations of a penny, while the prior year included income of $0.44. Excluding a write-down related to a discontinued research program, adjusted earnings from continuing operations rose to $1.39 from $1.24. Revenue increased 9.5 percent to $2.05 billion, or 4 percent excluding currency fluctuations.